留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

聚乙二醇衍生物及其蛋白药物修饰研究进展

张羽,  连治国,  徐明波,  冯芳

downloadPDF
文章导航 > 药学实践与服务  > 2018 >  36(4): 301-306,328
张羽, 连治国, 徐明波, 冯芳. 聚乙二醇衍生物及其蛋白药物修饰研究进展[J]. 药学实践与服务, 2018, 36(4): 301-306,328. doi: 10.3969/j.issn.1006-0111.2018.04.004
引用本文: 张羽, 连治国, 徐明波, 冯芳. 聚乙二醇衍生物及其蛋白药物修饰研究进展[J]. 药学实践与服务, 2018, 36(4): 301-306,328. doi: 10.3969/j.issn.1006-0111.2018.04.004
shu
ZHANG Yu, LIAN Zhiguo, XU Mingbo, FENG Fang. Advances in the development of PEG derivatives and pegylated protein drugs[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 301-306,328. doi: 10.3969/j.issn.1006-0111.2018.04.004
Citation: ZHANG Yu, LIAN Zhiguo, XU Mingbo, FENG Fang. Advances in the development of PEG derivatives and pegylated protein drugs[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 301-306,328. doi: 10.3969/j.issn.1006-0111.2018.04.004
shu

聚乙二醇衍生物及其蛋白药物修饰研究进展

doi: 10.3969/j.issn.1006-0111.2018.04.004
  • 1.

    中国药科大学, 江苏 南京 210009;北京双鹭药业股份有限公司, 北京 100041

  • 2.

    北京双鹭药业股份有限公司, 北京 100041

  • 3.

    中国药科大学, 江苏 南京 210009

Advances in the development of PEG derivatives and pegylated protein drugs

  • 1.

    China Pharmaceutical University, Nanjing 210009, China;Beijing SL Pharmaceutical Co., Ltd., Beijing 100041, China

  • 2.

    Beijing SL Pharmaceutical Co., Ltd., Beijing 100041, China

  • 3.

    China Pharmaceutical University, Nanjing 210009, China

  • 摘要: 聚乙二醇及其衍生物因其出色的亲水性、生物相容性、生物学惰性等特性而被广泛应用于蛋白药物修饰，其修饰可有效降低蛋白药物的免疫原性并延长体内半衰期。聚乙二醇衍生物的发展经历了第一代随机修饰，第二代特异性和功能性修饰，以及第三代分支型结构的应用。其应用也从简单的药物修饰扩展到生物传感、药物传输等方面。
    Abstract: Polyethylene glycol and its derivatives are widely used in protein drug modification due to the excellent hydrophilicity, biocompatibility and bioinertia. The pegylation makes it possible that protein has lower immunogenicity and longer half-life. PEG derivatives had undergone three generations, from random modifications, to site-specific and functional modifications, and then branched structures. The application of PEG derivatives also extends to biosensing and drug delivery. Advances in the development of PEG derivatives and pegylated protein drugs were reviewed in this paper.
  • [1] LAWRENCE P B, PRICE J L. How PEGylation influences protein conformational stability[J]. Curr Opin Chem Biol, 2016, 34:88-94.
    [2] PFISTER D, BOURGEAUX E, MORBIDELLI M. Kinetic modeling of protein PEGylation[J]. Chem Engin Sci, 2015, 137:816-827.
    [3] YANG Z, WANG J, LU Q, et al. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates[J]. Cancer Res, 2004, 64(18):6673-6678.
    [4] RODR GUEZMART NEZ JA, RIVERARIVERA I, SOL RJ, et al. Enzymatic activity and thermal stability of PEG-α-chymotrypsin conjugates[J]. Biotechnol Lett, 2009, 31(6):883-887.
    [5] 姜忠义, 许松伟, 王艳强. 蛋白质和肽类分子的聚乙二醇化化学[J]. 有机化学, 2003, 23(12):1340-1347.
    [6] ZALIPSKY S, SELTZER R, MENONRUDOLPH S. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins[J]. Biotechnol Appl Biochem, 1992, 15(1):100-114.
    [7] MIRON T, WILCHEK M. A simplified method for the preparation of succinimidyl carbonate polyethylene glycol for coupling to proteins[J]. Bioconjug Chem, 1993, 4(6):568-569.
    [8] ABUCHOWSKI A, KAZO GM, JR VC, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates[J]. Cancer Biochem Biophys, 1984, 7(2):175-186.
    [9] ABUCHOWSKI A,VAN ES T,PALCZUK NC,et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol[J]. J Biol Chem,1977,252(11):3578-3581.
    [10] GAIS H J, RUPPERT S. Modification and immobilization of proteins with polyethylene glycol tresylates and polysaccharide tresylates:Evidence suggesting a revision of the coupling mechanism and the structure of the polymer-polymer linkage[J]. Tetrahedron Lett, 1995, 36(22):3837-3838.
    [11] ZALIPSKY S, LEE C. Use of functionalized poly(ethylene glycol)s for modification of polypeptides[M]//Poly(Ethylene Glycol) Chemistry. Springer US, 1992:1-15.
    [12] WANG J, HU T, LIU Y, et al. Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase[J]. Anal Biochem, 2011, 412(1):114-116.
    [13] KINSTLER OB, BREMS DN, LAUREN SL, et al. Characterization and stability of N-terminally PEGylated rhG-CSF[J]. Pharm Res, 1996, 13(7):996-1002.
    [14] KINSTLER OB, GABRIEL NE, FARRAR CE, et al. N-terminally chemically modified protein-compositions and method:, DE 69509628 D1[P]. 1999.
    [15] FEE C J, DAMODARAN VB. Production of PEGylated proteins[M]//Biopharmaceutical Production Technology. 2012:199-222.
    [16] BROCCHINI S, GODWIN A, BALAN S, et al. Disulfide bridge based PEGylation of proteins[J]. Adv Drug Deliv Rev, 2008, 60(1):3-12.
    [17] TSUTSUMI Y, ONDA M, NAGATA S, et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38(LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity[J]. Proc Natl Acad Sci USA, 2000, 97(15):8548-8553.
    [18] BANGALORE S, KUMAR S, FUSARO M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus:mixed treatment comparison analysis of 22844 patient years of follow-up from randomised trials[J]. BMJ, 2012, 345:e5170.
    [19] PASUT G, VERONESE FM. State of the art in PEGylation:The great versatility achieved after forty years of research[J]. J Control Release, 2012, 161(2):461-472.
    [20] MORGENSTERN J, BAUMANN P, BRUNNER C, et al. Effect of PEG molecular weight and PEGylation degree on the physical stability of PEGylated lysozyme[J]. Int J Pharm, 2017, 519(1-2):408-417.
    [21] ROBERTS MJ, HARRIS JM. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy[J]. J Pharm Sci, 1998, 87(11):1440-1445.
    [22] ANDREW J. GARMAN S,BARRET KALINDJIAN. The preparation and properties of novel reversible polymer-protein conjugates 2-ω-Methoxypolyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activators[J]. Febs Lett, 1987, 223(2):361-365.
    [23] 田浤, 金宇灏, 陈阳建,等. 聚乙二醇氨基酸衍生物的合成及其对紫杉醇的修饰[J]. 中国药科大学学报, 2011, 42(1):78-82.
    [24] KIZILEL S, SCAVONE A, LIU X, et al. Encapsulation of pancreatic islets within nano-thin functional polyethylene glycol coatings for enhanced insulin secretion[J]. Tissue Engin Part A, 2010, 16(7):2217.
    [25] YOO MK, PARK IK, LIM HT, et al. Folate PEG superparamagnetic iron oxide nanoparticles for lung cancer imaging[J]. Acta Biomater, 2012, 8(8):3005-3013.
    [26] ZHANG C, YANG XL, YUAN YH, et al. Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives[J]. Biodrugs, 2012, 26(4):209. 209-215.
    [27] RYAN SIN AD M, MANTOVANI GIUSEPPE, WANG XUEXUAN, et al. Advances in PEGylation of important biotech molecules:delivery aspects[J]. Expert Opin Drug Deliv,2008,5(4):371-383.
    [28] VUGMEYSTER Y,ENTRICAN C A,JOYCE AP,et al.Pharmacokinetic,biodistribution and biophysical profiles of TNF nanobodies conjugated to linear or branched poly (ethylene glycol)[J].Bioconjug Chem,2012,23(7):1452-1462.
    [29] DAVIS, FF.The origin of pegnology[J]. Adv Drug Deliv Rev,2002,54(4):457-458.
    [30] DAVIS FF, VAN EST, PALCZUK NC. Non-immunogenic polypeptides:US, US 4179337 A[P]. 1979.
    [31] ABUCHOWSKI A,MCCOY JR,PALCZUK NC,et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase[J]. J Biol Chem,1977,252(11):3582-3586.
    [32] LEE CR,MCKENZIE CA,WEBSTER KD,et al. Pegademase bovine:replacement therapy for severe combined immunodeficiency disease[J]. DICP, 1991, 25(10):1092-1095
    [33] "Amgen 2016 Annual Report to Stockholders"[www.amgen.com/~/media/amgen/full/www-amgen-com/downloads/investors/2016-annual-report-letter-and-10k_restrict.ashx?la=en] 2016-annual-report-letter-and-10.pdf, 2017, p. 55
    [34] DE GRAAF AJ, KOOIJMAN M, HENNINK WE, et al. Nonnatural amino acids for site-specific protein conjugation[J]. Bioconjug Chem, 2009, 20(7):1281.
    [35] YANG BB, KIDO MA, MS MMS, et al. Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function[J]. J Clin Pharmacol, 2011, 50(5):295-306.
    [36] TURECEK PL, BOSSARD MJ, GRANINGER M,et al. BAX 855, a PEGylated rFVⅢ product with prolonged half-life. Development, functional and structural characterisation[J]. Hamostaseologie, 2012, 32(Suppl 1):S29-S38.
    [37] WORLD HEALTH ORGANIZATION. WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology. Switzerland:WHO Press, 2013. 91-92.
    [38] LI XL, LIU L, GAO JP, et al. Methods for identification of conjugation site on PEGylated protein[J]. Pharmaceutical Biotechnology, 2013.
    [39] YU W, YU C, WU L, et al. PEGylated recombinant human interferon-ω as a long-acting antiviral agent:structure, antiviral activity and pharmacokinetics[J]. Antiviral Res, 2014, 108:142-147.
    [40] JOHN B, SWAPAN C, JOHNSTON D. Characterization of poly(ethylene glycol)-modified superoxide dismutase:Comparison of capillary electrophoresis and matrix-assisted laser desorption/ionization mass spectrometry[J]. Analytical Chemistry, 1996, 68(18):3258-3264.
    [41] 李晶, 何辉, 程速远,等. 荧光胺衍生化法测定3种聚乙二醇化重组人生长激素的平均修饰率[J]. 药物分析杂志, 2014(8):1368-1373.
  • [1] 黎翔, 代鲜敏, 刘霞, 孙旸.  黄芪甲苷衍生物HHQ16上调α1酸性糖蛋白改善肝细胞脂质沉积 . 药学实践与服务, 2024, 42(4): 141-146. doi: 10.12206/j.issn.2097-2024.202309026
    [2] 王旭昉, 王彦婷, 姚春萌, 陆斌.  乳酸菌作为重组蛋白药物递送载体的研究 . 药学实践与服务, 2023, 41(): 1-5. doi: 10.12206/j.issn.2097-2024.202309021
    [3] 蓝晓红, 徐建新, 周永刚.  1例雌二醇/雌二醇地屈孕酮致下肢静脉血栓及危险因素分析 . 药学实践与服务, 2021, 39(2): 191-192. doi: 10.12206/j.issn.1006-0111.202009086
    [4] 张广军, 林玲, 陈丽娜, 高保安, 陈建明.  聚乙二醇400 介导的多西他赛脂肪乳剂与多西他赛注射液的稀释稳定性研究 . 药学实践与服务, 2015, 33(2): 119-121,175. doi: 10.3969/j.issn.1006-0111.2015.02.006
    [5] 周琴琴, 陈建明.  清蛋白作为药物载体的PEG化修饰研究进展 . 药学实践与服务, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
    [6] 任海峰, 赵英魁, 杨峰, 俞媛, 马志强.  微小RNA传递载体聚乙二醇-b-聚赖氨酸的合成及细胞毒性研究 . 药学实践与服务, 2014, 32(5): 362-365,373. doi: 10.3969/j.issn.1006-0111.2014.05.013
    [7] 胡晓, 胡容峰, 白中稳.  聚乙烯醇衍生物作为水凝胶材料的应用研究进展 . 药学实践与服务, 2013, 31(3): 169-172,180. doi: 10.3969/j.issn.1006-0111.2013.03.002
    [8] 祝芳.  环糊精及其衍生物在手性药物分离分析中的应用 . 药学实践与服务, 2010, 28(2): 94-96,111.
    [9] 朱占洲, 高翔, 朱海, 赵俊, 朱驹, 吕加国, 周有骏.  噻二唑类衍生物的合成与耐缺氧活性 . 药学实践与服务, 2010, 28(3): 220-222.
    [10] 孙亮, 黄晓瑾, 范颂杰, 俞世冲, 吴秋业.  6-(4-取代乙酰氨基苯基)-4，5-二氢-3(2H)哒嗪酮衍生物的合成及其抑制血小板聚集活性 . 药学实践与服务, 2008, (4): 278-281.
    [11] 樊毅, 朱子华, 陈晓慧, 张晓东, 李国栋, 高静, 丁雪鹰.  长效驱蚊霜野外现场驱避效果观察 . 药学实践与服务, 2008, (6): 450-451.
    [12] 董环文, 刘超美, 何秋琴, 赵荔华.  斑蝥素及其衍生物的合成及结构修饰的研究进展 . 药学实践与服务, 2008, (2): 97-102.
    [13] 徐国华, 雷招宝.  治疗慢性丙型肝炎新药——聚乙二醇干扰素α-2b . 药学实践与服务, 2005, (6): 350-353.
    [14] 范开华, 刘子文, 夏俊.  血卟啉二乙二醇对消化道肿瘤的光动力疗效观察 . 药学实践与服务, 2001, (2): 76-76.
    [15] 范开华, 温定量, 周明惠, 夏俊.  2,7,12,18-四甲基-3,8-二(1-甲氧乙基)-13,17-二(3-乙胺基丙基)卟啉衍生物的合成及其光敏活性 . 药学实践与服务, 1999, (6): 344-346.
    [16] 凌云, 柴逸峰, 李修禄.  罗汉金丹口服液中人参二醇的鉴别 . 药学实践与服务, 1993, (4): 291-294.
    [17] 缪朝玉, 苏定冯.  阿洛地平——一种新的长效钙拮抗剂 . 药学实践与服务, 1992, (4): 1-4.
    [18] 李力节, 周全.  以聚乙二醇与吐温—80的混合物作固体分散体的载体提高难溶性药物的溶解 . 药学实践与服务, 1991, (3): 59-60.
    [19] 景凡伟, 张紫洞.  透皮雌二醇与月经性偏头痛 . 药学实践与服务, 1990, (2): 86-86.
    [20] 王敏, 张紫洞.  乙醇、甘油和丙二醇对苯巴比妥钠稳定性的影响 . 药学实践与服务, 1987, (3): 82-82.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  5088
  • HTML全文浏览量:  522
  • PDF下载量:  1553
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-11-23
  • 修回日期:  2018-03-30

聚乙二醇衍生物及其蛋白药物修饰研究进展

doi: 10.3969/j.issn.1006-0111.2018.04.004
  • 1. 中国药科大学, 江苏 南京 210009;北京双鹭药业股份有限公司, 北京 100041
  • 2. 北京双鹭药业股份有限公司, 北京 100041
  • 3. 中国药科大学, 江苏 南京 210009
  • 收稿日期: 2017-11-23
  • 修回日期: 2018-03-30

摘要: 聚乙二醇及其衍生物因其出色的亲水性、生物相容性、生物学惰性等特性而被广泛应用于蛋白药物修饰，其修饰可有效降低蛋白药物的免疫原性并延长体内半衰期。聚乙二醇衍生物的发展经历了第一代随机修饰，第二代特异性和功能性修饰，以及第三代分支型结构的应用。其应用也从简单的药物修饰扩展到生物传感、药物传输等方面。

English Abstract

张羽, 连治国, 徐明波, 冯芳. 聚乙二醇衍生物及其蛋白药物修饰研究进展[J]. 药学实践与服务, 2018, 36(4): 301-306,328. doi: 10.3969/j.issn.1006-0111.2018.04.004
引用本文: 张羽, 连治国, 徐明波, 冯芳. 聚乙二醇衍生物及其蛋白药物修饰研究进展[J]. 药学实践与服务, 2018, 36(4): 301-306,328. doi: 10.3969/j.issn.1006-0111.2018.04.004
shu
ZHANG Yu, LIAN Zhiguo, XU Mingbo, FENG Fang. Advances in the development of PEG derivatives and pegylated protein drugs[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 301-306,328. doi: 10.3969/j.issn.1006-0111.2018.04.004
Citation: ZHANG Yu, LIAN Zhiguo, XU Mingbo, FENG Fang. Advances in the development of PEG derivatives and pegylated protein drugs[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 301-306,328. doi: 10.3969/j.issn.1006-0111.2018.04.004
shu

    全文HTML

参考文献 (41)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计